110884-53-2

Usage

Uses

Used in Pharmaceutical Research and Development:
5-Methoxy-1H-pyrazol-3-amine hydrochloride is used as a key intermediate for the synthesis of pharmaceutical compounds, leveraging its reactivity and structural properties to create new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Methoxy-1H-pyrazol-3-amine hydrochloride is utilized as a reagent, contributing to the formation of complex organic molecules that are integral to the development of novel chemical entities.
Used in Medicinal Chemistry Processes:
5-Methoxy-1H-pyrazol-3-amine hydrochloride is employed as a component in medicinal chemistry, where it aids in the design and synthesis of bioactive molecules with specific therapeutic targets, thereby advancing drug discovery and development efforts.
Used in Drug Targeting:
5-Methoxy-1H-pyrazol-3-amine hydrochloride is used as a building block in the development of drugs that target various diseases and conditions, capitalizing on its chemical properties to enhance the efficacy and selectivity of these therapeutic agents.
Overall, 5-Methoxy-1H-pyrazol-3-amine hydrochloride plays a pivotal role in the pharmaceutical and chemical industries, driving innovation in drug discovery and the creation of new therapeutic agents.

Upstream product

• 41307-23-7 5-methoxy-1H-pyrazol-3-amine 
• 70138-31-7 2-cyano-1,1,1-trimethoxyethane 

Relevant academic research and scientific papers

Discovery of 5-chloro- N 2-[(1 S)-1-(5-fluoropyrimidin-2-yl) ethyl]- N 4-(5-methyl-1 H -pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the jak/stat pathway

The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematological malignancies characterized by clonal expansion of one or more myeloid lineages. The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs. Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor. 9e inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent physical properties and preclinical pharmacokinetics, and is currently being evaluated in Phase I clinical trials.

PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.